Reduced metabolic disorders in the tubule cells by SGLT2 inhibition was accompanied by the alleviation of hyperfiltration, mesangial expansion, albuminuria and tubulointerstitial fibrosis and immune infiltration. This evidence concerns the gene SLC5A2 and Other metabolic disease.